Joint Global Coordinator and Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator & Joint Bookrunner to SynAct Pharma in its SEK 150m Fully Guaranteed Rights Issue.
SynAct is a publicly listed Swedish biotech focused on the development of novel and first in class agonists that target the melanocortin system, which plays a pivotal role in controlling inflammatory responses. Lead candidate, AP1189, selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression and is studied in rheumatoid arthritis, nephrotic syndrome, and COVID-19 induced acute respiratory stress syndrome.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: